BR9911150A - Método de tratamento - Google Patents

Método de tratamento

Info

Publication number
BR9911150A
BR9911150A BR9911150-0A BR9911150A BR9911150A BR 9911150 A BR9911150 A BR 9911150A BR 9911150 A BR9911150 A BR 9911150A BR 9911150 A BR9911150 A BR 9911150A
Authority
BR
Brazil
Prior art keywords
treatment method
paroxetine
solvate
humans
administration
Prior art date
Application number
BR9911150-0A
Other languages
English (en)
Inventor
Martin X Steiner
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9911150A publication Critical patent/BR9911150A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO DE TRATAMENTO" Processo para promover o corte ou a diminuição do hábito de fumar ou prevenir a recaída do hábito, que compreende a administração de uma quantidade de paroxetina efetiva, não tóxica ou um sal ou solvato seu, farmaceuticamente aceitável, para humanos que dela necessitem.
BR9911150-0A 1998-06-16 1999-06-16 Método de tratamento BR9911150A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (1)

Publication Number Publication Date
BR9911150A true BR9911150A (pt) 2001-03-06

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911150-0A BR9911150A (pt) 1998-06-16 1999-06-16 Método de tratamento

Country Status (20)

Country Link
EP (1) EP1087766A4 (pt)
JP (1) JP2002518330A (pt)
KR (1) KR20010052895A (pt)
CN (1) CN1305379A (pt)
AP (1) AP2000002002A0 (pt)
AU (1) AU740749B2 (pt)
BG (1) BG105127A (pt)
BR (1) BR9911150A (pt)
CA (1) CA2335236A1 (pt)
CZ (1) CZ20004698A3 (pt)
EA (1) EA003584B1 (pt)
GB (1) GB9812941D0 (pt)
HU (1) HUP0102507A3 (pt)
IL (1) IL139943A0 (pt)
NO (1) NO20006383D0 (pt)
NZ (1) NZ508532A (pt)
PL (1) PL345261A1 (pt)
SK (1) SK19192000A3 (pt)
WO (1) WO1999065491A1 (pt)
ZA (1) ZA200007396B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645523B2 (en) * 2000-08-28 2003-11-11 Synthon Bct Technologies, Llc Paroxetine compositions and processes for making the same
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Also Published As

Publication number Publication date
EP1087766A1 (en) 2001-04-04
ZA200007396B (en) 2002-02-27
HUP0102507A3 (en) 2003-12-29
BG105127A (en) 2001-11-30
AP2000002002A0 (en) 2000-12-31
EP1087766A4 (en) 2001-11-21
CZ20004698A3 (cs) 2002-02-13
SK19192000A3 (sk) 2001-05-10
EA200100041A1 (ru) 2001-06-25
AU740749B2 (en) 2001-11-15
HUP0102507A2 (hu) 2002-05-29
NO20006383L (no) 2000-12-14
NZ508532A (en) 2003-08-29
CA2335236A1 (en) 1999-12-23
JP2002518330A (ja) 2002-06-25
CN1305379A (zh) 2001-07-25
GB9812941D0 (en) 1998-08-12
EA003584B1 (ru) 2003-06-26
IL139943A0 (en) 2002-02-10
KR20010052895A (ko) 2001-06-25
NO20006383D0 (no) 2000-12-14
AU4688599A (en) 2000-01-05
WO1999065491A1 (en) 1999-12-23
PL345261A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
DE69939651D1 (de) Behandlung hyperproliferativer erkrankungen
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
CO5690131A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento de transtornos del snc
BR0110420A (pt) Agonistas muscarìnicos
BR0107732A (pt) Método para prevenir ou tratar uma doença
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0109703A (pt) Derivados de piperazina
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
BR0009776A (pt) Método de tratamento
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
PT998287E (pt) Utilizacao de levobupivacaina
PT1140102E (pt) Compostos de triazinona para tratar doencas causadas por sarcosystis, neospora etoxoplasma
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
BR9911150A (pt) Método de tratamento
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
BR9809376A (pt) Pregnan-3-ol-20-onas
BR0316054A (pt) Compostos para tratamento de dependência e privação de tabaco

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.